Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: Ready-to-wear versus made-to-measure tool

Haematologica

Volumn 97, Issue 4, 2012, Pages 631-632

  Della Porta, Matteo G ^a   Ambaglio, Ilaria ^a   Ubezio, Marta ^a   Travaglino, Erica ^a   Pascutto, Cristiana ^a   Malcovati, Luca ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Comorbidity; Myelodysplastic syndromes; Prognosis; Survival

Indexed keywords

ADULT COMORBIDITY EVALUATION 27; COMORBIDITY; CONGESTIVE HEART FAILURE; HEART INFARCTION; HUMAN; LETTER; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MDS-SPECIFIC COMORBIDITY INDEX; MYELODYSPLASTIC SYNDROME; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROMUSCULAR DISEASE; PARALYSIS; PROGNOSIS; RESPIRATORY TRACT DISEASE; SOLID TUMOR; SURVIVAL;

COMORBIDITY; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 84859469339     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.057323     Document Type: Letter

References (10)

1. Della Porta MG, Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica. 2009;94(5):602-606.
2. Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, Lei X, Shan J, Kantarjian HM, Suarez-Almazor ME. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29(16): 2240-2246.
3. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. Jama. 2004;291(20):2441-2447.
4. Geraci JM, Escalante CP, Freeman JL, Goodwin JS. Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol. 2005;23(30):7399-7404.
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
6. Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M and others. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96(10):1433-40.
7. Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N, Haas R, Germing U. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009;94 (5):729-732.
8. Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96(3):441-9.
9. Breccia M, Federico V, Latagliata R, Mercanti C, D'Elia GM, Cannella L, Loglisci G, Salaroli A, Santopietro M, Alimena G. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res 2011;35(2):159-162.
10. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19(6):716-723.